hydromorphone has been researched along with furosemide in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (12.50) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (50.00) | 29.6817 |
2010's | 3 (37.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Strassburg, CP; Tukey, RH | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Baert, B; Beetens, J; Bodé, S; De Spiegeleer, B; Deconinck, E; Lambert, J; Slegers, G; Slodicka, M; Stoppie, P; Van Gele, M; Vander Heyden, Y | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Blake, JW; Combie, J; Nugent, TE; Tobin, T | 1 |
Perri, GA | 1 |
2 review(s) available for hydromorphone and furosemide
Article | Year |
---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for hydromorphone and furosemide
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
Topics: Anti-Inflammatory Agents; Cell Membrane Permeability; Cluster Analysis; Drug Evaluation, Preclinical; Humans; Models, Biological; Predictive Value of Tests; Quantitative Structure-Activity Relationship; Regression Analysis; Skin; Skin Absorption | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Furosemide, Patella vulgata beta-glucuronidase and drug analysis: conditions for enhancement of the TLC detection of apomorphine, butorphanol, hydromorphone, nalbuphine, oxymorphone and pentazocine in equine urine.
Topics: Animals; Apomorphine; Butorphanol; Cattle; Chromatography, Thin Layer; Female; Furosemide; Glucuronidase; Helix, Snails; Horses; Hydrolysis; Hydromorphone; Mollusca; Nalbuphine; Oxymorphone; Pentazocine; Species Specificity | 1982 |
Ascites in patients with cirrhosis.
Topics: Abdominal Pain; Aged; Analgesics, Opioid; Ascites; Catheters, Indwelling; Diet, Sodium-Restricted; Diuretics; End Stage Liver Disease; Fatal Outcome; Furosemide; Humans; Hydromorphone; Liver Cirrhosis, Alcoholic; Male; Palliative Care; Paracentesis; Peritoneal Cavity; Spironolactone | 2013 |